Recent News

  • ‘Tis the Season for Vaccination

    Eric Dein, MD
    syringe,needle,vaccine
    As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic diseases, vaccinations can be confusing and worrisome. For clinicians with limited bandwidth, these conversations can feel like added responsibilities in an already overfull schedule.
    Read Article
Dr. John Cush Tweet
@RheumNow
Lancet: A Public Health Policy Call Out for Osteoarthritis In honor of World Arthritis Day (Oct. 12th), The Lancet has published a public Health Policy report is to "outline a globally relevant roadmap to address the osteoarthritis identity problem, focusing on health policy https://t.co/XTRDJnOEGn
Dr. John Cush Tweet
@RheumNow
Placebo beats probiotics in PsA. And nearly 90% of well-controlled RA patients may be able to cut their targeted therapy dose in half. Dr. Jack Cush breaks down the findings worth a closer look in this week's RheumNow podcast, Troubles with ‘Gut Feelings’. Probiotics in PsA: https://t.co/Aqy4HxGHbU
Dr. John Cush Tweet
@RheumNow
Yale researchers propose repurposing the epilepsy drug, lacosamide, to treat osteoarthritis. In animal models, delivered as a hydrogel conjugate IA, improved cartilage repair, slowed deterioration, & reduced pain. Chosen as it blocks Sodium channels, esp Nav1.7 involved in pain https://t.co/ERJ2xPEyzl
Dr. John Cush Tweet
@RheumNow
Colchicine & Statins: A significant interaction? Colchicine is frequently used in rheumatologic practice. Current ACR guidelines for gout management support anti-inflammatory prophylaxis, including colchicine, during initiation and uptitration of urate-lowering therapy https://t.co/BFF9UTuLIl
Dr. John Cush Tweet
@RheumNow
Single center study of Probiotics in #PsA showed no benefit. 66 moderately active PsA pts (PASDAS>3.2) on stable Tx: Rx probiotic vs PBO x 12 wks. 56 pts analyzed, PASDAS <3 responders: 43% probiotic vs 65% PBO (P 0.167), w/ no change in gut permeability markers or stool https://t.co/0JUZ8SrRuw
Dr. John Cush Tweet
@RheumNow
92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/w5Gc3ntej0
Dr. John Cush Tweet
@RheumNow
Can DMARD Doses Be Safely Reduced for RA Patients? Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean https://t.co/MyjZdRaGb4
Dr. John Cush Tweet
@RheumNow
Colchicine & Statins: A significant interaction? Colchicine is frequently used in rheumatologic practice. Current ACR guidelines for gout management support anti-inflammatory prophylaxis, including colchicine, during initiation and uptitration of urate-lowering therapy https://t.co/eyDbfpQajN
Dr. John Cush Tweet
@RheumNow
Surgery for 1st MTP Osteoarthritis Hallux rigidus, or osteoarthritis of the first metatarsophalangeal joint (MTPJ), is common, but treatment options and long-term outcomes remain poorly understood. A 12-month clinical trial showed that first MTPJ arthrodesis (compared to https://t.co/fHda4GK4vA

Video

From the Blog

rheumthought

Treatment for Obesity and Inflammation, but at what Cost?

Jonathan Kay, MD
Kay RT cover still

The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases. 

Read Article

Podcasts

  • Troubles with ‘Gut Feelings’
  • Don’t Hold the JAK (10.9.2026)
  • PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives
  • Remission – Believe it or Not (10.2.2026)
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Clinical dilemmas in axSpA and PsA

Sponsored by UCB
UCB October RX Update
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie October RX Update
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post

Obesity – Inflammation – PsA

Sponsored by Lilly Medical Affairs
Lilly October
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×